Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma

Bone Marrow Transplantation volume 54, pages 943–960 (2019)Cite this article

Subjects

Abstract

High-dose chemotherapy and autologous hematopoietic cell transplantation (HDT-AHCT) remains an effective therapy in lymphoma. Over the past several decades, HDT with BEAM (carmustine, etoposide, cytarabine, and melphalan) and CBV (cyclophosphamide, carmustine, and etoposide) have been the most frequently used preparatory regimens for AHCT in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). This article reviews alternative combination conditioning regimens, as well as novel transplant strategies that have been developed, to reduce transplant-related toxicity while maintaining or improving efficacy. These data demonstrate that incorporation of maintenance therapy posttransplant might be the best way to improve outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Eng J Med. 1987;316:1493–8.

    Article  CAS  Google Scholar 

  2. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–27.

    Article  CAS  PubMed  Google Scholar 

  4. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9. https://doi.org/10.1200/JCO.2011.40.2719.

    Article  CAS  PubMed  Google Scholar 

  5. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Eng J Med. 1995;333:1540–5.

    Article  CAS  Google Scholar 

  6. Skipper HE, Schabel FM Jr., Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep. 1964;35:1–111.

    CAS  PubMed  Google Scholar 

  7. Skipper HE. Perspectives in cancer chemotherapy: therapeutic design. Cancer Res. 1964;24:1295–302.

    CAS  PubMed  Google Scholar 

  8. Skipper HE, Schabel FM Jr., Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970;54:431–50.

    CAS  PubMed  Google Scholar 

  9. Skipper HE, Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res. 1970;30:1883–97.

    CAS  PubMed  Google Scholar 

  10. Mc FW, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood. 1959;14:503–21.

    Google Scholar 

  11. Clifford P, Clift RA, Duff JK. Nitrogen-mustard therapy combined with autologous marrow infusion. Lancet. 1961;1:687–90.

    Article  CAS  PubMed  Google Scholar 

  12. Pegg DE. A quantitative study of bone marrow grafting: implications for human bone marrow infusion. Br J Cancer. 1962;16:400–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kurnick NB. Autologous and isologous bone marrow storage and infusion in the treatment of myelo-suppresson. Transfusion. 1962;2:178–87.

    Article  CAS  PubMed  Google Scholar 

  14. Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood. 1978;52:85–95.

    CAS  PubMed  Google Scholar 

  15. Appelbaum FR, Deisseroth AB, Graw RG Jr., Herzig GP, Levine AS, Magrath IT, et al. Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer. 1978;41:1059–63.

    Article  CAS  PubMed  Google Scholar 

  16. Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS, et al. Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1989;73:2086–92.

    CAS  PubMed  Google Scholar 

  17. Carella AM, Santini G, Santoro A, Coser P, Frassoni F, Martinengo M, et al. Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin’s disease. Eur J Cancer Clin Oncol. 1985;21:607–13.

    Article  CAS  PubMed  Google Scholar 

  18. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med. 1986;104:163–8.

    Article  CAS  PubMed  Google Scholar 

  19. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.

    Article  CAS  PubMed  Google Scholar 

  20. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

    Article  CAS  PubMed  Google Scholar 

  21. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2006;37:1017–22. https://doi.org/10.1038/sj.bmt.1705371.

    Article  CAS  PubMed  Google Scholar 

  22. Lazarus HM, Carreras J, Boudreau C, Loberiza FR Jr., Armitage JO, Bolwell BJ, et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008;14:1323–33.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803–9.

    Article  CAS  PubMed  Google Scholar 

  24. Thieblemont C, Antal D, Lacotte-Thierry L, Delwail V, Espinouse D, Michallet AS, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer. 2005;104:1434–41. https://doi.org/10.1002/cncr.21313.

    Article  CAS  PubMed  Google Scholar 

  25. Ritchie DS, Seymour JF, Grigg AP, Roberts AW, Hoyt R, Thompson S, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol. 2007;86:101–5. https://doi.org/10.1007/s00277-006-0193-2.

    Article  CAS  PubMed  Google Scholar 

  26. LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119:2093–9. https://doi.org/10.1182/blood-2011-07-369629.

    Article  CAS  PubMed  Google Scholar 

  27. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355–62. https://doi.org/10.1111/j.1365-2141.2012.09174.x.

    Article  CAS  PubMed  Google Scholar 

  28. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677–84. https://doi.org/10.1182/blood-2004-10-3883.

    Article  CAS  PubMed  Google Scholar 

  29. Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40:443–50. https://doi.org/10.1038/sj.bmt.1705752.

    Article  CAS  PubMed  Google Scholar 

  30. Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33:405–10. https://doi.org/10.1038/sj.bmt.1704367.

    Article  CAS  PubMed  Google Scholar 

  31. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652–7.

    Article  CAS  PubMed  Google Scholar 

  32. McCarthy PL Jr., Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant. 2013;19:1116–23. https://doi.org/10.1016/j.bbmt.2013.04.027.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19:1395–404. https://doi.org/10.1200/JCO.2001.19.5.1395.

    Article  CAS  PubMed  Google Scholar 

  34. Lazarus HM, Loberiza FR Jr., Zhang MJ, Armitage JO, Ballen KK, Bashey A, et al. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the Autologous Blood and Marrow Transplant Registry (ABMTR). Bone Marrow Transplant. 2001;27:387–96. https://doi.org/10.1038/sj.bmt.1702796.

    Article  CAS  PubMed  Google Scholar 

  35. Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol. 2003;21:2320–5. https://doi.org/10.1200/JCO.2003.11.103.

    Article  CAS  PubMed  Google Scholar 

  36. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616–23.

    Article  CAS  PubMed  Google Scholar 

  37. Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011;96:1128–35. https://doi.org/10.3324/haematol.2010.030320.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a national lymphocare study and center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2017. https://doi.org/10.1016/j.bbmt.2017.12.771.

    Article  PubMed  Google Scholar 

  39. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2013;31:1624–30. https://doi.org/10.1200/JCO.2012.47.1862.

    Article  CAS  PubMed  Google Scholar 

  40. Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21:2324–31.

    Article  CAS  PubMed  Google Scholar 

  41. Kornacker M, Stumm J, Pott C, Dietrich S, Sussmilch S, Hensel M, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009;20:722–8.

    Article  CAS  PubMed  Google Scholar 

  42. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687–93. https://doi.org/10.1182/blood-2008-03-147025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53. https://doi.org/10.1182/blood-2011-09-370320.

    Article  CAS  PubMed  Google Scholar 

  44. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27:6101–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Hoster EMB, Forstpointner R, Pfreundschuh M, Trümper L, Hallek M, Wörmann B, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood. 2009;114:880.

    Google Scholar 

  46. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32:273–81. https://doi.org/10.1200/JCO.2013.49.2454.

    Article  PubMed  Google Scholar 

  47. Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998;16:13–8.

    Article  CAS  PubMed  Google Scholar 

  48. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol. 2003;120:793–800.

    Article  PubMed  Google Scholar 

  49. Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.

    Article  CAS  PubMed  Google Scholar 

  50. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–8. https://doi.org/10.1038/sj.leu.2404306.

    Article  CAS  PubMed  Google Scholar 

  51. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19:958–63. https://doi.org/10.1093/annonc/mdn022.

    Article  CAS  PubMed  Google Scholar 

  52. Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6:e452. https://doi.org/10.1038/bcj.2016.63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14:1768–75

    Article  CAS  PubMed  Google Scholar 

  54. Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica. 2003;88:1372–7.

    CAS  PubMed  Google Scholar 

  55. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–9. https://doi.org/10.1200/JCO.2012.46.0188.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk. 2013;13:664–70. https://doi.org/10.1016/j.clml.2013.07.005.

    Article  PubMed  Google Scholar 

  57. Frei E 3rd, Holden SA, Gonin R, Waxman DJ, Teicher BA. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemother Pharmacol. 1993;33:113–22.

    Article  CAS  PubMed  Google Scholar 

  58. Chao NJ, Stein AS, Long GD, Negrin RS, Amylon MD, Wong RM, et al. Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood. 1993;81:319–23.

    CAS  PubMed  Google Scholar 

  59. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23(5 Suppl 10):3–15.

    CAS  PubMed  Google Scholar 

  60. Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012;40:800–10. https://doi.org/10.1016/j.exphem.2012.06.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Jones RB, Matthes S, Shpall EJ, Fisher JH, Stemmer SM, Dufton C, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst. 1993;85:640–7.

    Article  CAS  PubMed  Google Scholar 

  62. Jones RB, Shpall EJ, Ross M, Coniglio D, Affronti ML, Peters WP. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. Cancer Chemother Pharmacol. 1990;26:155–6.

    Article  CAS  PubMed  Google Scholar 

  63. Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21:1046–53. https://doi.org/10.1016/j.bbmt.2015.02.005.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Robinson SP, Boumendil A, Finel H, Dreger P, Sureda A, Hermine O, et al. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party. Bone Marrow Transplant. 2018. https://doi.org/10.1038/s41409-018-0196-3.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Grisariu S, Shapira MY, Or R, Avni B. Thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan (TECAM) conditioning regimen for autologous stem cell transplantation in lymphoma. Clin Lymphoma, Myeloma & Leuk. 2018;18:272–9. https://doi.org/10.1016/j.clml.2018.02.008.

    Article  Google Scholar 

  66. Joffe E, Rosenberg D, Rozovski U, Perry C, Kirgner I, Trestman S, et al. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma. Bone Marrow Transplant. 2018;53:29–33. https://doi.org/10.1038/bmt.2017.205.

    Article  CAS  PubMed  Google Scholar 

  67. Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant. 2016;51:212–8. https://doi.org/10.1038/bmt.2015.273.

    Article  CAS  PubMed  Google Scholar 

  68. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118:3419–25. https://doi.org/10.1182/blood-2011-04-351924.

    Article  CAS  PubMed  Google Scholar 

  69. Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol. 2018. https://doi.org/10.1002/ajh.25077.

    Article  PubMed  Google Scholar 

  70. Jaimovich G, Ostriz MBR, Castro M, Riera L, Banchieri A, Foncuberta MC. et al. Autologous stem cell transplantation (ASCT) with benda-CV (bendamustine, cyclophosphamide, etoposide) in non-Hodgkin (non-HO) and Hodgkin (HL) lymphoma patients (pts). Biol Blood Marrow Transplant. 2017;23:S84

    Article  Google Scholar 

  71. Kim JW, Lee HJ, Yi HG, Kim BS, Bang SM, Kim JS, et al. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am J Hematol. 2012;87:479–83. https://doi.org/10.1002/ajh.23150.

    Article  CAS  PubMed  Google Scholar 

  72. Olivieri JMF, Pelosini M, Fama A, Rattotti S, Giannoccaro M, Carli G, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on patients from Fondazione Italiana Linfomi (Fil). Biol Blood Marrow Transplant. 2018. https://doi.org/10.1016/j.bbmt.2018.05.018.

    Article  PubMed  Google Scholar 

  73. Sharma A, Kayal S, Iqbal S, Malik PS, Raina V. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. +. 2013;2:489 https://doi.org/10.1186/2193-1801-2-489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Kothari J, Foley M, Peggs KS, Mackenzie S, Thomson K, Morris E, et al. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM. Bone Marrow Transplant. 2016;51:1397–9. https://doi.org/10.1038/bmt.2016.134.

    Article  CAS  PubMed  Google Scholar 

  75. Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1343–9. https://doi.org/10.1016/j.bbmt.2006.08.039.

    Article  CAS  PubMed  Google Scholar 

  76. Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2000;25:1243–8. https://doi.org/10.1038/sj.bmt.1702433.

    Article  CAS  PubMed  Google Scholar 

  77. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2007;40:919–24. https://doi.org/10.1038/sj.bmt.1705841.

    Article  CAS  PubMed  Google Scholar 

  78. Tarella C, Zallio F, Caracciolo D, Cuttica A, Corradini P, Gavarotti P, et al. High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia. 2001;15:256–63.

    Article  CAS  PubMed  Google Scholar 

  79. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol. 1993;11:704–11. https://doi.org/10.1200/JCO.1993.11.4.704.

    Article  CAS  PubMed  Google Scholar 

  80. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012;18:1677–86. https://doi.org/10.1016/j.bbmt.2012.05.011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, et al. Vorinostat combined with high-dose gemcitabine, busulfan, and melphalan with autologous stem cell transplantation in patients with refractory lymphomas. Biol Blood Marrow Transplant. 2015;21:1914–20. https://doi.org/10.1016/j.bbmt.2015.06.003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, et al. Phase II trial of high-dose gemcitabine/busulfan/melphalan with autologous stem cell transplantation for primary refractory or poor-risk relapsed hodgkin lymphoma. Biol Blood Marrow Transplant. 2018. https://doi.org/10.1016/j.bbmt.2018.02.020.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013;19:410–7. https://doi.org/10.1016/j.bbmt.2012.10.029.

    Article  CAS  PubMed  Google Scholar 

  84. Davidson MSD, Duggan P, Daly A, Shafey M. Phase I/II study of infusional gemcitabine and high-dose melphalan conditioning prior to autologous stem cell transplantation for patients with relapsed/refractory lymphoma: interim safety analysis. Blood. 2017;130:4534.

    Google Scholar 

  85. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:461–7. https://doi.org/10.1200/JCO.2005.05.117.

    Article  CAS  PubMed  Google Scholar 

  86. Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D. et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:90–5. Doi: https://doi.org/10.1200/JCO.2007.11.9248.

    Article  CAS  PubMed  Google Scholar 

  87. Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118:4706–14. https://doi.org/10.1002/cncr.27418.

    Article  CAS  PubMed  Google Scholar 

  88. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662–8. https://doi.org/10.1200/JCO.2012.45.9453.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, et al. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2017;52:1120–5. https://doi.org/10.1038/bmt.2017.88.

    Article  CAS  PubMed  Google Scholar 

  90. Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, et al. Updated results of rituximab pre- and post-BEAM with or without (90)yttrium ibritumomab tiuxetan during autologous transplant for diffuse large B-cell lymphoma. Clin Cancer Res. 2018. https://doi.org/10.1158/1078-0432.CCR-17-3561.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Victor A, Chow JR, Shields A, Fisher DR, Appelbaum FR, Cassaday RD, et al. A phase II trial evaluating the efficacy of radioiodinated tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-Hodgkin’s lymphoma. Blood. 2017;130:2018.

    Article  Google Scholar 

  92. Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin’s disease (HD). SFGM/GELA Study Group. Ann Oncol. 1999;10:1485–8.

    Article  CAS  PubMed  Google Scholar 

  93. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin’s lymphoma: a monocenter prospective study. Am J Hematol. 2007;82:122–7. https://doi.org/10.1002/ajh.20790.

    Article  CAS  PubMed  Google Scholar 

  94. Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008;26:5980–7. https://doi.org/10.1200/JCO.2007.15.5887.

    Article  PubMed  Google Scholar 

  95. Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007;13:594–600. https://doi.org/10.1016/j.bbmt.2007.01.072.

    Article  PubMed  Google Scholar 

  96. Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, et al. Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent Hodgkin lymphoma: a SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant. 2018;24:700–7. https://doi.org/10.1016/j.bbmt.2017.12.798.

    Article  PubMed  Google Scholar 

  97. Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, et al. Tandem haematopoietic stem cell transplantation for high risk relapsed/refractory Hodgkin lymphoma: a LYSA study. Br J Haematol. 2018;181:341–9. https://doi.org/10.1111/bjh.15184.

    Article  PubMed  Google Scholar 

  98. Hohloch K, Sahlmann CO, Lakhani VJ, Wulf G, Glass B, Hasenkamp J, et al. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue. Ann Hematol. 2011;90:1307–15. https://doi.org/10.1007/s00277-011-1199-y.

    Article  CAS  PubMed  Google Scholar 

  99. Monjanel H, Deconinck E, Perrodeau E, Gastinne T, Delwail V, Moreau A, et al. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study. Biol Blood Marrow Transplant. 2011;17:935–40. https://doi.org/10.1016/j.bbmt.2010.11.017.

    Article  PubMed  Google Scholar 

  100. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462–9. https://doi.org/10.1200/JCO.2012.41.9416.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010. https://doi.org/10.1200/JCO.2010.28.1618.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C. et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Eng J Med. 2017;377:1250–60. https://doi.org/10.1056/NEJMoa1701769.

    Article  Google Scholar 

  103. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9. https://doi.org/10.1200/JCO.2011.38.0410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–62. https://doi.org/10.1016/S0140-6736(15)60165-9.

    Article  CAS  PubMed  Google Scholar 

  105. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709–17. https://doi.org/10.1182/blood-2017-05-780049.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Saleh K, Danu A, Koscielny S, Legoupil C, Pilorge S, Castilla-Llorente C, et al. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leuk Lymphoma. 2017. https://doi.org/10.1080/10428194.2017.1403019.

    Article  Google Scholar 

  107. Tsang EVD, Loscocco F, Gerrie AS, Visani G, Power M, Guiducci B, et al. Comparative effectiveness of high-dose bendamustine-EAM versus BEAM in patients with relapsed/refractory classical hodgkin lymphoma undergoing autologous stem cell transplantation. Blood. 2017;130:3291.

    Google Scholar 

  108. Boisjoly JA BP, Cohen S, Ahmad I, Bambace N, Bernard L, Delisle JS, et al. Impact of carmustine (BCNU) substitution for bendamustine in the conditioning regimen prior to autologous hematopoietic cell transplantation for the treatment of lymphoma. Blood. 2017;130:2022.

    Google Scholar 

  109. Nathan SBS, McWilliams D, Schultz K, Geswein L, Maciejewski J, Venugopal P, et al. Rituxan-benda-eam (R-be-EAM) and rituxan-BEAM (R-BEAM) have similar efficacy in patients with in B cell non-Hodgkin lymphoma (B-NHL) patients (Pts) undergoing autologous stem cell transplantation (AutoSCT). Biol Blood Marrow Transplant. 2017;23:S139.

    Article  Google Scholar 

  110. Ninos CJJ, Mably M, Reed M, Hutson P, Williams Z, Callander NS, et al. Outcomes of BeEAM (bendamustine, etoposide, cytarabine, melphalan) compared to BEAM (carmustine, etoposide, cytarabine, melphalan) for high dose chemotherapy followed by autologous stem cell transplant. Biol Blood Marrow Transplant. 2018;24:S134.

    Article  Google Scholar 

  111. Jain NCA, Sood N, Arabandi A, Sengupta K, Chakrabartty J. Bendamustine based conditioning regime (BACE-bendamustine, cytarabine, cyclophosphamide and etoposide) for patients with lymphoma undergoing autologous stem cell transplant. Biol Blood Marrow Transplant. 2016;22:S121–2.

    Article  Google Scholar 

  112. Chakrabartty JJN, Sarada P, Sengupta K, Sood N, Arabandi A, Chakravarti A, et al. Bendamustine-based conditioning regime (BACE-bendamustine, cytarabine, cyclophosphamide and etoposide) for patients with lymphoma undergoing autologous stem cell transplant. Biol Blood Marrow Transplant. 2017;23:S133.

    Google Scholar 

  113. Sakellari I, Mallouri D, Batsis I, Apostolou C, Konstantinou V, Abela EM, et al. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Leuk Lymphoma. 2015;56:3071–81. https://doi.org/10.3109/10428194.2015.1028054.

    Article  CAS  PubMed  Google Scholar 

  114. Berber I, Erkurt MA, Nizam I, Koroglu M, Kaya E, Kuku I, et al. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. Int J Clin Exp Med. 2015;8:16308–14.

    PubMed  PubMed Central  Google Scholar 

  115. Zhang H, Graiser M, Hutcherson DA, Dada MO, McMillan S, Ali Z, et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1287–94. https://doi.org/10.1016/j.bbmt.2012.02.006.

    Article  CAS  PubMed  Google Scholar 

  116. Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res. 2011;35:183–7. https://doi.org/10.1016/j.leukres.2010.07.016.

    Article  CAS  PubMed  Google Scholar 

  117. Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002;81:96–102. https://doi.org/10.1007/s00277-001-0413-8.

    Article  CAS  PubMed  Google Scholar 

  118. Nieto YBR, Hosing C, Jones RB, Valdez BC, Kingham A, Ahmed S, et al. Comparison of high-dose gemcitabine, busulfan and melphalan (GEM/BU/MEL) and BEAM in concurrent patient cohorts with mature T-cell non-Hodgkin’s lymphoma (T-NHL) receiving an autologous stem cell transplantation (ASCT). Biol Blood Marrow Transplant. 2016;22:S227–8.

    Article  Google Scholar 

  119. Villa D, Crump M, Keating A, Panzarella T, Feng B, Kuruvilla J. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann Oncol. 2013;24:1603–9. https://doi.org/10.1093/annonc/mdt029.

    Article  CAS  PubMed  Google Scholar 

  120. Ji JLT, Kuang P, Liu Z, Dong T, Liu J. Chidamide, a HDAC inhibitor, combined with cladribine, high dose gemcitabine and busulfan with autologous stem cell transplantation in patients with relapsed/refractory and poor-risk lymphoma. Blood. 2017;130:3288.

    Google Scholar 

  121. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–206. https://doi.org/10.1200/JCO.2012.48.3685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, et al. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol. 2018;11:87 https://doi.org/10.1186/s13045-018-0631-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Kaplan LD, Jung S-H, Stock W, Bartlett NL, Pitcher B, Byrd JC. et al. Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (Alliance) 50403. Blood. 2015;126:337.

    Google Scholar 

  124. Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014;166:77–83. https://doi.org/10.1111/bjh.12846.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Jakub Svoboda LES, Daniel JLandsburg, Sunita DwivedyNasta, Anthony RMato, Wei-Ting Hwang, Sarah Jordan Nagle, et al. Lenalidomide maintenance after autologous stem cell transplant in patients with high-risk relapsed/refractory lymphomas is feasible and compares favorably to historical controls: results of a phase I/II trial. Blood. 2016;128:4639.

    Google Scholar 

  126. Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, et al. A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. Leuk Lymphoma. 2015;56:1043–9. https://doi.org/10.3109/10428194.2014.963073.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This research is supported in part by grants from the National Institute of Health, National Cancer Institute (P01 CA23766 and P30 CA008748). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

All the authors examined the available data and wrote the review.

Author information

Authors and Affiliations

  1. Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Parastoo B. Dahi, Craig S. Sauter & Sergio A. Giralt

  2. Weill Cornell Medical College, New York, NY, USA

    Parastoo B. Dahi, Craig S. Sauter & Sergio A. Giralt

  3. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA

    Hillard M. Lazarus

Authors
  1. Parastoo B. Dahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hillard M. Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Craig S. Sauter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sergio A. Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Parastoo B. Dahi.

Ethics declarations

Conflict of interest

HML has been a consultant and promotional speaker for Seattle Genetics. The other authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dahi, P.B., Lazarus, H.M., Sauter, C.S. et al. Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. Bone Marrow Transplant 54, 943–960 (2019). https://doi.org/10.1038/s41409-018-0378-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0378-z

This article is cited by

Search

Advanced search

Quick links